Amidst a backdrop of global economic challenges and shifting trade dynamics, Asian markets have been navigating a complex landscape. For investors considering alternatives to the major indices, penny stocks—often representing smaller or newer companies—remain an intriguing option. While the term "penny stock" might seem outdated, these investments can still offer substantial opportunities when backed by strong financial health and potential for growth.
Operating results put Cathay Pacific Airways (SEHK:293) in focus
Cathay Pacific Airways (SEHK:293) has attracted fresh attention after reporting December 2025 and full year traffic figures, with double digit year on year growth in both passenger volumes and cargo tonnage.
See our latest analysis for Cathay Pacific Airways.
The HK$12.58 share price has been supported by an 11.72% 90 day share price return and a 27.65% 1 year total shareholder return, suggesting momentum has been building...
Why East Buy Holding (SEHK:1797) is in focus ahead of earnings
East Buy Holding (SEHK:1797) is drawing attention as it heads into its 28 January 2026 earnings release, with investors closely watching revenue growth, margin trends and management guidance.
See our latest analysis for East Buy Holding.
At a share price of HK$23.08, East Buy Holding has recently seen a 27.73% 1 month share price return and a 44.97% 1 year total shareholder return. However, the 3 year total shareholder return of a...
In recent research released before 26 January 2026, Citi and UOB Kay Hian highlighted that China Overseas Land & Investment faces expected profit margin pressure, deeper write-offs, and weaker 2025 earnings across China’s stressed real-estate sector.
At the same time, both brokers continued to single out China Overseas Land & Investment as one of the relatively stronger developers within a sector undergoing restructuring and impairment-driven reset.
We’ll now examine how this combination of...
CStone Pharmaceuticals (SEHK:2616) has moved to refresh its governance and incentive structure, pairing a large equity award package for director and staff with board changes that bring new financial expertise and committee leadership.
See our latest analysis for CStone Pharmaceuticals.
These governance moves come as CStone’s share price trades at HK$5.43, with a 1-year total shareholder return of 132.05% contrasting with a 5-year total shareholder return of 52.03% and a softer 90-day share...
In January 2026, Shanghai Fudan Microelectronics Group issued unaudited guidance for 2025, expecting revenue of about RMB 3,930,000,000 to RMB 4,030,000,000, but projecting net profit attributable to shareholders to fall to roughly RMB 190,000,000 to RMB 283,000,000 and core net profit after non-recurring items to RMB 125,000,000 to RMB 185,000,000.
The company links this profit compression to inventory impairment after earlier stockpiling, higher research and development expenses from...
Lingbao Gold Group has appointed corporate law expert Mr. Huang Hui as an independent non-executive director and committee chair, and shareholders have approved amendments to the company’s Articles of Association at an extraordinary general meeting held on 22 January 2026.
This combination of governance-focused board refresh and updated Articles signals an increased emphasis on oversight, legal expertise, and rule-setting at the top of the company.
We’ll now examine how the appointment of...
